Answers are grounded in this paper and cite their sources.
This study is the first to explore dose-response relationships in the treatment of fibromyalgia with low-dose naltrexone. Future placebo-controlled randomized clinical trials are needed, and according to our findings, 4.5 mg, which has previously been used, seems to be a relevant test dose. We recommend that future studies include additional nonpain fibromyalgia symptoms as outcome measures.
No takes yet. Share an insight, caveat, or question.
Bruun et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: